Hypertension as a predictive factor of Sunitinib activity [1]

Annals of Oncology

Volumn 18, Issue 6, 2007, Pages 1117-

  Rixe, O ^a   Billemont, B ^a   Izzedine, Hassan ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; SUNITINIB;

ADULT; AGED; CLINICAL ARTICLE; DISEASE CONTROL; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSGEUSIA; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; HAIR COLOR; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LETTER; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; TESTIS DISEASE;

EID: 34447343347     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm184     Document Type: Letter

References (3)

1. Motzer RJ, Hutson TE, Tomczak P et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Proc. Am Soc Clin Oncol. J. Clin. Oncol. Part I. Vol 24, No. 18S (June 20 Supplement), LB3, 2006.
2. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
3. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.